CCL11 is a C-C motif chemokine that serves as a potent chemoattractant central to both allergic and non-allergic inflammatory responses. It exerts its primary effects by binding to the CCR3 receptor on leukocyte surfaces, driving migration of eosinophils, basophils, macrophages, and dendritic cells 1. Beyond immune recruitment, CCL11 promotes angiogenesis through activation of the PI3K/Akt signaling pathway and induces chemotaxis of endothelial cells. In asthma, CCL11 (also known as eotaxin or eotaxin-1) is produced in lung tissues and recruits eosinophils from blood vessels into airways 2. Recent evidence suggests CCL11 also contributes to cellular aging in lung fibroblasts through reactive oxygen species production and DNA damage response activation, with elevated levels correlating with shorter telomere length in leukocytes from asthmatic children 3. Beyond allergic disease, CCL11 dysfunction associates with pancreatic cancer, where suppression of CCL11 expression promotes tumor progression by reducing protective intratumoral eosinophil accumulation 4. Elevated plasma CCL11 has been documented in neuroinflammatory disorders and COVID-19 patients with neurologic complications 5. The monoclonal antibody bertilimumab represents a clinical approach targeting this axis. Earlier small-molecule CCR3 antagonists showed promise in blocking eosinophil recruitment 2, though translation to human therapeutics remains incomplete.